|MDACC Study No:||2013-0160 (clinicaltrials.gov NCT No: NCT01882946)|
|Title:||A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors|
|Principal Investigator:||Vivek Subbiah|
|Treatment Agent:||Dendritic Cells|
|Study Description:||The goal of Phase I of this clinical research study is to find the highest |
of DCVax-Direct that can be given to patients with a locally advanced or
metastatic solid tumor cancer.
The goal of Phase II of this study is to learn about the safety of DCVax-Direct
learn if it can help to control the disease by causing an immune response
cancer cells. Another goal of this part of the study is to learn if
DCVax-Direct causes any changes to the tumor.
This is the first study using DCVax-Direct in humans.